End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.11 USD | +4.31% |
|
+4.58% | -24.17% |
28/06 | Goldman Sachs Downgrades Sagimet Biosciences to Hold From Buy, Price Target at $6 | MT |
06/06 | Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.17% | 109M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- SGMT Stock
- News Sagimet Biosciences Inc.
- Sagimet Biosciences Appoints COO Anthony Rimac as CFO, Effective Aug. 1